- Home
- VINP vs CRGX Comparison
VINP vs CRGX Comparison
Compare VINP & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- CRGX
- Stock Information
- Founded
- VINP 2009
- CRGX 2021
- Country
- VINP Brazil
- CRGX United States
- Employees
- VINP N/A
- CRGX N/A
- Industry
- VINP Investment Managers
- CRGX
- Sector
- VINP Finance
- CRGX
- Exchange
- VINP Nasdaq
- CRGX Nasdaq
- Market Cap
- VINP 641.7M
- CRGX 621.4M
- IPO Year
- VINP 2021
- CRGX 2023
- Fundamental
- Price
- VINP $10.10
- CRGX $13.46
- Analyst Decision
- VINP Strong Buy
- CRGX Strong Buy
- Analyst Count
- VINP 2
- CRGX 6
- Target Price
- VINP $13.50
- CRGX $31.80
- AVG Volume (30 Days)
- VINP 72.5K
- CRGX 231.3K
- Earning Date
- VINP 02-05-2025
- CRGX 03-20-2025
- Dividend Yield
- VINP 6.34%
- CRGX N/A
- EPS Growth
- VINP N/A
- CRGX N/A
- EPS
- VINP 0.60
- CRGX N/A
- Revenue
- VINP $88,217,697.00
- CRGX N/A
- Revenue This Year
- VINP $17.23
- CRGX N/A
- Revenue Next Year
- VINP $51.06
- CRGX N/A
- P/E Ratio
- VINP $16.88
- CRGX N/A
- Revenue Growth
- VINP 9.03
- CRGX N/A
- 52 Week Low
- VINP $9.01
- CRGX $10.91
- 52 Week High
- VINP $11.85
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- VINP 55.39
- CRGX 47.00
- Support Level
- VINP $9.61
- CRGX $12.51
- Resistance Level
- VINP $10.25
- CRGX $15.75
- Average True Range (ATR)
- VINP 0.24
- CRGX 1.09
- MACD
- VINP 0.07
- CRGX 0.17
- Stochastic Oscillator
- VINP 86.01
- CRGX 52.74
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.